Obesity Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast to 2031

1.1 The obesity market will grow significantly during the forecast period, reaching sales of $37.1 billion in 2031
1.2 Key players will maintain their competitive position
1.3 While the outlook in obesity improves, opportunities remain to improve patient outcomes
1.4 Late-stage pipeline therapies are anticipated to drive growth in the obesity market
1.5 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3.1 Etiology and pathophysiology
3.1.1 Overview
3.1.2 Etiology
3.1.3 Pathophysiology
3.2 Classification or staging systems

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.3.1 Total prevalence of overweight
4.3.2 Total prevalence of obesity
4.3.3 Diagnosed prevalence of overweight
4.3.4 Diagnosed prevalence of obesity
4.4 7MM forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Total prevalent cases of overweight
4.4.4 Total prevalent cases of obesity
4.4.5 Total prevalent cases by BMI class
4.4.6 Diagnosed prevalent cases of overweight, obesity, and obesity by BMI class
4.4.7 Diagnosed incident cases of bariatric surgery
4.5 Epidemiological forecast for overweight and obesity (2021-31)
4.5.1 Total prevalent cases of overweight
4.5.2 Total prevalent cases of obesity
4.5.3 Diagnosed prevalent cases of overweight
4.5.4 Age-specific diagnosed prevalent cases of overweight
4.5.5 Sex-specific diagnosed prevalent cases of overweight
4.5.6 Diagnosed prevalent cases of obesity
4.5.7 Age-specific diagnosed prevalent cases of obesity
4.5.8 Sex-specific diagnosed prevalent cases of obesity
4.5.9 Diagnosed prevalent cases of obesity by BMI class
4.5.10 Diagnosed incident cases of bariatric surgery
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis

5.1 Diagnosis and treatment overview
5.1.1 Diagnosis overview
5.1.2 Treatment overview
5.2 KOL Insights on Disease Management
5.2.1 Guidelines on diagnosis and treatment
5.2.2 Treatment approach

6.1 Overview

7.1 Overview
7.2 Increased efficacy and weight loss maintenance
7.3 Longer-acting therapy
7.4 Cost of therapy
7.5 Increased public awareness
7.6 Availability/accessibility of specialists

8.1 Overview
8.1.1 Development of novel targets
8.1.2 Development of oral agents
8.2 Clinical Trials Design
8.2.1 Clinical endpoints for obesity
8.2.2 Inclusion and exclusion criteria for obesity
8.2.3 Trial duration

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment

11.1 Overview
11.2 Deal-making trends

12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and Barriers

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - key opinion leaders interviewed for this report
13.4.1 Key opinion leaders
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Reviewers
13.6.5 Vice President of Disease Analysis and Intelligence
13.6.6 Global Head and EVP of Healthcare Operations and Strategy

• Contact the Publisher

Table 1: Obesity: key metrics in the 7MM
Table 2: Classifications of obesity as outlined by the WHO
Table 3: Classification systems for obesity based on BMI cut-off points
Table 4: Risk factors and comorbidities for obesity
Table 5: Treatment guidelines for obesity
Table 6: Top 10 deals by value, 2017-22
Table 7: Obesity market - global drivers and barriers, 2021-31
Table 8: Key events impacting sales for obesity in the US, 2021-31
Table 9: Obesity market - drivers and barriers in the US, 2021-31
Table 10: Key events impacting sales for obesity in the 5EU, 2021-2031
Table 11: Obesity market - drivers and barriers in the 5EU, 2021-31
Table 12: Key events impacting sales for Obesity in Japan, 2021-31
Table 13: Obesity market - drivers and barriers in Japan, 2021-2031
Table 14: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for obesity in 2021 and 2031
Figure 2: Analysis of the company portfolio gap in obesity during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that the publisher expects to be licensed for the treatment of obesity during the forecast period
Figure 4: Factors involved in the etiology of obesity
Figure 5: Pathophysiological manifestation of obesity
Figure 6: 7MM, total prevalence of overweight, men and women, ages =5 years, 2011-31 (%)
Figure 7: 7MM, total prevalence of obesity, men and women, ages =5 years, 2011-31 (%)
Figure 8: 7MM, diagnosed prevalence of overweight, men and women, ages =5 years, 2011-31 (%)
Figure 9: 7MM, diagnosed prevalence of obesity, men and women, ages =5 years, 2011-31 (%)
Figure 10: 7MM, sources used to forecast the total and diagnosed prevalent cases of overweight and obesity
Figure 11: 7MM, sources used and not used to forecast the total and diagnosed prevalent cases of Class I, Class II, and Class III obesity
Figure 12: 7MM, sources used and not used to forecast diagnosed incidence of bariatric surgery
Figure 13: 7MM, total prevalent cases of overweight, men and women, ages =5 years, 2021 (N)
Figure 14: 7MM, total prevalent cases of obesity, men and women, ages =5 years, 2021 (N)
Figure 15: 7MM, diagnosed prevalent cases of overweight, men and women, ages =5 years, 2021 (N)
Figure 16: 7MM, diagnosed prevalent cases of overweight by age, men and women, 2021 (N)
Figure 17: 7MM, diagnosed prevalent cases of overweight by sex, ages =5 years, 2021 (N)
Figure 18: 7MM, diagnosed prevalent cases of obesity, men and women, ages =5 years, 2021 (N)
Figure 19: 7MM, diagnosed prevalent cases of obesity by age, men and women, 2021 (N)
Figure 20: 7MM, diagnosed prevalent cases of obesity by sex, ages =5 years, 2021 (N)
Figure 21: 7MM, diagnosed prevalent cases of obesity by BMI class, men and women, ages =5 years, 2021 (N)
Figure 22: 7MM, diagnosed incident cases of bariatric surgery, men and women, all ages, 2021 (N)
Figure 23: BMI chart as a diagnostic technique for obesity
Figure 24: Treatment algorithm for obesity
Figure 25: Unmet needs and opportunities in obesity
Figure 26: Overview of the development pipeline in obesity
Figure 27: Key late-stage trials for the promising pipeline agents that the publisher expects be licensed for obesity in the 7MM during the forecast period
Figure 28: Competitive assessment of the recently approved agents and late-stage pipeline agents that the publisher expects to be licensed for the treatment of obesity during the forecast period
Figure 29: Competitive assessment of the marketed and pipeline drugs benchmarked against the standard of care, Wegovy
Figure 30: Analysis of the company portfolio gap in obesity during the forecast period
Figure 31: Global (7MM) sales forecast by country for obesity in 2021 and 2031
Figure 32: Global (7MM) sales forecast by drug for obesity in 2021 and 2031
Figure 33: Sales forecast by drug for obesity in the US in 2021 and 2031
Figure 34: Sales forecast by drug for obesity in the 5EU in 2021 and 2031
Figure 35: Sales forecast by drug for obesity in Japan in 2021 and 2031